Events & Presentations Investor Relations Overview Press Releases Scientific Publications & Presentations Corporate Deck Events & Presentations Press Kit Corporate Governance Financial Info Stock Info Analyst Coverage Investor Resources Events and Presentations Upcoming Events Past Events Presentations ESG Report Presentations Intellia Therapeutics Company Overview – February 2023 NTLA-2002 Interim Clinical Data Update – November 14, 2022 NTLA-2001 and NTLA-2002 Interim Clinical Data Update – September 16, 2022 In vivo CRISPR/Cas9 editing of KLHB1 in patients with HAE – September 16, 2022 NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial – June 24, 2022 J.P. Morgan Healthcare Conference Presentation – January 12, 2022 NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial – June 28, 2021 Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences and Intellia Ex Vivo Pipeline Updates – June 22, 2021 Click here to view a complete list of prior publications and presentations. Contact IR
Presentations Intellia Therapeutics Company Overview – February 2023 NTLA-2002 Interim Clinical Data Update – November 14, 2022 NTLA-2001 and NTLA-2002 Interim Clinical Data Update – September 16, 2022 In vivo CRISPR/Cas9 editing of KLHB1 in patients with HAE – September 16, 2022 NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial – June 24, 2022 J.P. Morgan Healthcare Conference Presentation – January 12, 2022 NTLA-2001 for ATTR Amyloidosis: Interim Clinical Results from Ongoing Phase 1 Trial – June 28, 2021 Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences and Intellia Ex Vivo Pipeline Updates – June 22, 2021 Click here to view a complete list of prior publications and presentations.
Launch of New Universal CAR-T Company with Cellex and Blackstone Life Sciences and Intellia Ex Vivo Pipeline Updates – June 22, 2021
